Monoclonal antibodies

#Antibodies #Antibody-based therapeutics #Bio-Rad Laboratories #In Focus Report #Monoclonal antibodies

The future of antibody based drugs: Where are the opportunities?

This report will:   Provide an overview of the monoclonal antibody (mAbs) industry: market value, key on the future of antibody-based drug players, opportunities and the future  Explore what’s next for antibody-based drugs and where the opportunity is coming from  Include an interview Bio-Rad’s… Read More

#DDW eBooks #Intelligence

Antibodies
#Antibodies #Antibody-based therapeutics #Bio-Rad Laboratories #In Focus Report #Monoclonal antibodies

DDW In Focus e-report on the future of antibody-based drugs

Created by DDW and sponsored by Bio-Rad, The future of antibody-based drugs: Where are the opportunities and what does the future hold? is a free In Focus report, available here.  This report will:   Provide an overview of the monoclonal… Read More

#News

Hospital patient on ventilator
#Covid-19 #Covid-19 treatment #FDA #InflaRx #Monoclonal antibodies

FDA okays Gohibic for emergency use in Covid-19 patients

Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of Covid-19 in hospitalised adults. The monoclonal anti-human complement factor C5a antibody should be initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or… Read More

#News #Trending News

Cholesterol test
#Heart disease #Monoclonal antibodies #Phase I trial #Vaccines #Vaxxinity

LDL cholesterol vaccine ‘could be a game-changer’

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. The drug works by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). “We’re… Read More

#Editor's Choice #News

Monoclonal antibodies
#Biomarkers #Cancer research #Monoclonal antibodies #Oncology #Pancreatic cancer #Phase I trial

‘Encouraging’ data for monoclonal antibody in advanced cancers

Purple Biotech has revealed positive new results from exploratory analyses conducted as part of a Phase I dose escalation study into CM24 plus nivolumab for advanced cancer. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma (PDAC), two patients with colorectal… Read More

#Cancer Research #News

Lecanemab
#Alzheimer's #Biogen #Eisai #FDA #GlobalData #Monoclonal antibodies #United States

Uncertainty surrounds monoclonal antibody for Alzheimer’s

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData.  Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease… Read More

#News #Regulatory

PrismA ELISA kit
#Assay development optimisation & technology #Biopharmaceuticals #Cytiva #Monoclonal antibodies

New PrismA ELISA kit for impurity testing

This article is sponsored by Cytiva. The new PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA chromatography resin and Fibro PrismA chromatography adsorbers. The kit is used during the development and manufacture of monoclonal antibody (mAb) biopharmaceuticals. … Read More

#News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

Listen to the first DDW Highlights podcast for 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The drug discovery industry has hit the ground running in 2023 with… Read More

#News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

This week in drug discovery (2-6 January)

News round-up for 2-6 January by DDW Digital Content Editor Diana Spencer. The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, where there has been good news in pancreatic, urothelial and uveal cancers. … Read More

#News

Antibodies attack Covid-19
#AstraZeneca #Covid-19 #Covid-19 treatment #Immunity #Monoclonal antibodies

Accelerated development for Covid-19 monoclonal antibody

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery.  AstraZeneca has initiated the SUPERNOVA Phase I/III trial of AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of Covid-19, following the company licensing AZD3152 from… Read More

#Covid-19 #News #Trending News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

Listen now: Last episode of DDW Highlights for 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting… Read More

#News

IgE antibodies
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

Harnessing the power of IgE antibodies to create novel therapeutics

From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech company is developing a first-in-class therapy for the millions of people whose daily lives are limited by food… Read More

Webinar date:
Brought to you by SPT Labtech
#Webinars

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

This week in drug discovery (12-16 December)

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories: … Read More

#News

#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

Accessing broad B cell diversity to rapidly identify high-value rabbit monoclonal antibodies

Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. This presentation will introduce Berkeley Lights’ newest antibody discovery workflow, the Opto Memory B Discovery workflow, and share how customers are using the… Read More

Webinar date:
Brought to you by Berkeley Lights
#Webinars

A woman scratching her skin
#Antibodies #Atopic dermatitis #Dermatology #Immunotherapy #Monoclonal antibodies

New dermatitis treatment shows promising long-term results

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis.  Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have… Read More

#News #Trending News

IgE antibody
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

Exclusive webinar: Harness the power of IgE antibodies

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More

Webinar date:
Brought to you by SPT Labtech
#Editor's Choice #News